Literature DB >> 24771584

Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.

Peter Birner1, Stefan Pusch, Christo Christov, Stiliana Mihaylova, Kalina Toumangelova-Uzeir, Sevdalin Natchev, Sebastian F Schoppmann, Andrey Tchorbanov, Berthold Streubel, Jochen Tuettenberg, Marin Guentchev.   

Abstract

BACKGROUND: Recently, isocitrate dehydrogenase 1 (IDH1) was identified as a major participant in glioma pathogenesis. At present, the enzymatic activity of the protein has been the main topic in investigating its physiological function, but its signaling pathway allocation was unsuccessful. Interestingly, proteins regulated by phosphoinositide 3-kinase (PI3K)/Akt signaling, are among the top downregulated genes in gliomas associated with high percentage of IDH1 and IDH2 mutations. The aim of this study was to investigate a hypothetical relation between IDH1 and PI3K signaling.
METHODS: The presence of mutant IDH1 and markers for active PI3K/Akt signaling, present as phosphorylated Akt and podoplanin (PDPN), were investigated in a discovery cohort of 354 patients with glioma. In vitro experiments were used to confirm functional links.
RESULTS: This study shows an inverse correlation between mutant IDH1 and markers for active PI3K/Akt signaling. In support of a functional link between these molecules, in vitro expression of mutant IDH1 inhibited Akt phosphorylation in a 2-hydroxyglutarate-dependent manner.
CONCLUSIONS: This study provides patient tumor and in vitro evidence suggesting that mutant IDH1 inhibits PI3K/Akt signaling.
© 2014 American Cancer Society.

Entities:  

Keywords:  Akt; IDH1; PDPN; astrocytoma; glioblastoma; glioma

Mesh:

Substances:

Year:  2014        PMID: 24771584     DOI: 10.1002/cncr.28732

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Authors:  Peter M Clark; Wilson X Mai; Timothy F Cloughesy; David A Nathanson
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

2.  High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.

Authors:  Lei Wang; Luyao Zhang; Weigao Shen; Yanbo Liu; Yinan Luo
Journal:  Exp Ther Med       Date:  2015-12-02       Impact factor: 2.447

3.  IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.

Authors:  Timucin Avsar; Tansu Bilge Kose; Muhammed Deniz Oksal; Gizem Turan; Turker Kilic
Journal:  Mol Biol Rep       Date:  2022-08-07       Impact factor: 2.742

4.  Podoplanin increases migration and angiogenesis in malignant glioma.

Authors:  Stefan J Grau; Fabian Trillsch; Joerg-Christian Tonn; Roland H Goldbrunner; Elfriede Noessner; Peter J Nelson; Irene von Luettichau
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 5.  Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.

Authors:  Julia Riedl; Cihan Ay
Journal:  Semin Thromb Hemost       Date:  2019-04-30       Impact factor: 4.180

6.  Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.

Authors:  Julia Riedl; Matthias Preusser; Pegah Mir Seyed Nazari; Florian Posch; Simon Panzer; Christine Marosi; Peter Birner; Johannes Thaler; Christine Brostjan; Daniela Lötsch; Walter Berger; Johannes A Hainfellner; Ingrid Pabinger; Cihan Ay
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

Review 7.  Cancer-associated pathways and biomarkers of venous thrombosis.

Authors:  Yohei Hisada; Nigel Mackman
Journal:  Blood       Date:  2017-08-14       Impact factor: 22.113

8.  MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein.

Authors:  Yilong Yao; Jun Ma; Yixue Xue; Ping Wang; Zhen Li; Zhiqing Li; Yi Hu; Xiuli Shang; Yunhui Liu
Journal:  Mol Oncol       Date:  2014-11-20       Impact factor: 6.603

Review 9.  Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Biomedicines       Date:  2021-05-30

Review 10.  Metabolic consequences of oncogenic IDH mutations.

Authors:  Seth J Parker; Christian M Metallo
Journal:  Pharmacol Ther       Date:  2015-05-05       Impact factor: 13.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.